Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis
Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis
复制标题
癌症患者化疗后粒细胞集落刺激因子的疗效和耐受性：系统评价和贝叶斯网络荟萃分析
DOI：
10.1038/s41598-019-51982-4
复制
发表时间：
2019-10
影响因子：
4.6
通讯作者：
Li Yong
中科院分区：
文献类型：
--
作者：
Wang Yong;Chen Lin;Liu Fen;Zhao Ning;Xu Liyao;Fu Biqi;Li Yong
The optimum granulocyte colony-stimulating factor (G-CSF) treatment for cancer patients after being treated with cytotoxic chemotherapy remains unknown. Therefore, a systematic review and Bayesian network meta-analysis were performed to assess the efficacy and tolerability of 11 G-CSF drugs on patients after chemotherapy. A total of 73 randomized controlled trials (RCTs) containing 15,124 cancer patients were included for the final network meta-analysis. Compared with pegfilgrastim, there were a higher risk with filgrastim for incidence of febrile neutropenia (FN) (OR [95% CI]: 1.63 [1.07, 2.46]), and a higher risk with short-acting G-CSF (S-G-CSF) biosimilar and lenograstim for incidence of bone pain (BP) (OR [95% CI]: 6.45 [1.10, 65.73], 5.12 [1.14, 26.12], respectively). Mecapegfilgrastim, lipegfilgrastim and balugrastim were best G-CSF drugs in reducing FN (cumulative probabilities: 58%, 15%, 11%, respectively). S-G-CSF biosimilar, empegfilgrastim, and long-acting G-CSF (L-G-CSF) biosimilar were best G-CSF drugs in reducing severe neutropenia (SN) (cumulative probabilities: 21%, 20%, 15%, respectively). Mecapegfilgrastim, balugrastim, lipegfilgrastim and L-G-CSF biosimilar were best G-CSF drugs in reducing BP (cumulative probabilities: 20%, 14%, 8%, 8%, respectively). Mecapegfilgrastim, lipegfilgrastim and balugrastim might be the most appreciate G-CSF drugs with both good efficacy and tolerability when treating cancer patients after cytotoxic chemotherapy.
登录
查看更多内容
影响因子：
45.3
作者：
BUI, BN;CHEVALLIER, B;COURCHABERNAUD, V
通讯作者：
COURCHABERNAUD, V
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
10.1007/s00520-015-2963-7
发表时间：
2016-04
期刊：
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
影响因子：
--
作者：
Lee KH;Kim JY;Lee MH;Han HS;Lim JH;Park KU;Park IH;Cho EK;Yoon SY;Kim JH;Choi IS;Park JH;Choi YJ;Kim HJ;Jung KH;Kim SY;Oh DY;Im SA
通讯作者：
Im SA
DOI：
10.6004/jnccn.2008.0012
发表时间：
2008-02
期刊：
Journal of the National Comprehensive Cancer Network : JNCCN
影响因子：
--
作者：
J. Crawford;D. Dale;N. Kuderer;E. Culakova;M. Poniewierski;D. Wolff;G. Lyman
通讯作者：
J. Crawford;D. Dale;N. Kuderer;E. Culakova;M. Poniewierski;D. Wolff;G. Lyman
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group